share_log

Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors

Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors

Zymeworks重點介紹Zanidatamab Zovodotin在HER2陽性腫瘤中的早期試驗數據
Benzinga Real-time News ·  2022/09/13 09:34
  • Zymeworks Inc (NASDAQ:ZYME) presented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin (ZW49) for HER2-positive tumors.
  • The data were presented at the European Society for Medical Oncology Annual Congress.
  • A total of 77 patients were enrolled in this first-in-human trial, designed to determine the maximum tolerated dose of zanidatamab zovodotin, characterize its safety and tolerability, and evaluate anti-tumor activity in HER2-expressing cancers as monotherapy.
  • Also Read: Zymeworks Turns Down All Blue's Hostile Bid.
  • At the time of the analysis, the maximum tolerated dose had not yet been reached.
  • In the trial, zanidatamab zovodotin was shown to have a manageable safety profile, with the majority of adverse events being mild or moderate.
  • In patients with HER2-positive cancers treated with zanidatamab zovodotin at 2.5 mg/kg Q3W, the confirmed objective response rate was 31%, and the disease control rate was 72%.
  • The Phase 1 trial continues to enroll patients to study safety. The company expects to present the results of this dosing regimen at a medical meeting in 2023.
  • Price Action: ZYME shares are up 0.20% at $4.95 during the market session on the last check Tuesday.
  • Zymeworks Inc.納斯達克公司(JYME)公佈了評估zanidatamab zovodotin(ZW49)治療HER2陽性腫瘤的第一階段試驗的初步結果。
  • 這些數據是在歐洲醫學腫瘤學學會年會上公佈的。
  • 共有77名患者參加了這項首次人體試驗，旨在確定zanidatamab zovodotin的最大耐受量，表徵其安全性和耐受性，並評估HER2表達的癌症作為單一療法的抗腫瘤活性。
  • 另請閲讀： Zymeworks拒絕了All Blue的敵意收購.
  • 在進行分析時，尚未達到最大耐受量。
  • 在試驗中，zanidatamab zovodotin被證明具有可控的安全性，大多數不良事件為輕度或中度。
  • 在HER2陽性癌症患者中，Zanidatamab Zovodotin 2.5 mg/kg q3w治療後，確認的客觀緩解率為31%，疾病控制率為72%。
  • 1期試驗繼續招募患者進行安全性研究。該公司預計將在2023年的一次醫學會議上公佈這種劑量方案的結果。
  • 價格行動：在週二尾盤交易中，ZYME股價上漲0.20%，至4.95美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論